Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
暂无分享,去创建一个
[1] A. Evdokiou,et al. Death to the bad guys: Targeting cancer via Apo2L/TRAIL , 2005, Apoptosis.
[2] F. Khuri,et al. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. , 2004, Journal of the National Cancer Institute.
[3] F. Khuri,et al. p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site , 2004, Cancer Research.
[4] S. Toyooka,et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types , 2004, International journal of cancer.
[5] J. Redondo,et al. Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Decoy Receptor TRAIL-R3 Is Up-regulated by p53 in Breast Tumor Cells through a Mechanism Involving an Intronic p53-binding Site* , 2004, Journal of Biological Chemistry.
[6] M. Oren,et al. Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.
[7] J. Manfredi,et al. p53 and apoptosis: it's not just in the nucleus anymore. , 2003, Molecular cell.
[8] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[9] J. Herman,et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. , 2002, Cancer research.
[10] W. el-Deiry,et al. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.
[11] S. Benchimol. p53-dependent pathways of apoptosis , 2001, Cell Death and Differentiation.
[12] Sam W. Lee,et al. p53 induction of heparin‐binding EGF‐like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades , 2001, The EMBO journal.
[13] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[14] A. Fornace,et al. Death and decoy receptors and p53-mediated apoptosis , 2000, Leukemia.
[15] W. El-Deiry,et al. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.
[16] A. Fornace,et al. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[18] H. Friess,et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract , 1999, Oncogene.
[19] R. Lotan,et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells , 1999, Oncogene.
[20] V. Dixit,et al. Death receptors: signaling and modulation. , 1998, Science.
[21] V. Dixit,et al. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.
[22] C. Smith,et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.
[23] A. Gurney,et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.
[24] R. Lotan,et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. , 1997, Cancer research.
[25] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[26] I. Krantz,et al. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.
[27] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.